Literature DB >> 18325866

Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells.

Fraser P Coxon1, Keith Thompson, Anke J Roelofs, F Hal Ebetino, Michael J Rogers.   

Abstract

Bisphosphonates (BPs) target bone due to their high affinity for calcium ions. During osteoclastic resorption, these drugs are released from the acidified bone surface and taken up by osteoclasts, where they act by inhibiting the prenylation of small GTPases essential for osteoclast function. However, it remains unclear exactly how osteoclasts internalise BPs from bone and whether other cells in the bone microenvironment can also take up BPs from the bone surface. We have investigated this using a novel fluorescently-labelled alendronate analogue (FL-ALN), and by examining changes in protein prenylation following treatment of cells with risedronate (RIS). Confocal microscopic analysis showed that FL-ALN was efficiently internalised from solution or from the surface of dentine by resorbing osteoclasts into intracellular vesicles. Accordingly, unprenylated Rap1A accumulated to the same extent whether osteoclasts were cultured on RIS-coated dentine or with RIS in solution. By contrast, J774 macrophages internalised FL-ALN and RIS from solution, but took up comparatively little from dentine, due to their inability to resorb the mineral. Calvarial osteoblasts and MCF-7 tumour cells internalised even less FL-ALN and RIS, both from solution and from the surface of dentine. Accordingly, the viability of J774 and MCF-7 cells was drastically reduced when cultured with RIS in solution, but not when cultured on dentine pre-coated with RIS. However, when J774 macrophages were co-cultured with rabbit osteoclasts, J774 cells that were adjacent to resorbing osteoclasts frequently internalised more FL-ALN than J774 cells more distant from osteoclasts. This was possibly a result of increased availability of BP to these J774 cells due to transcytosis through osteoclasts, since FL-ALN partially co-localised with trancytosed, resorbed matrix protein within osteoclasts. In addition, J774 cells occupying resorption pits internalised more FL-ALN than those on unresorbed surfaces. These data demonstrate that osteoclasts are able to take up large amounts of BP, due to their ability to release the BP from the dentine surface during resorption. By contrast, non-resorbing cells take up only small amounts of BP that becomes available due to natural desorption from the dentine surface. However, BP uptake by non-resorbing cells can be increased when cultured in the presence of resorbing osteoclasts.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18325866     DOI: 10.1016/j.bone.2007.12.225

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  64 in total

1.  A comparative effectiveness pilot study of teriparatide for medication-related osteonecrosis of the jaw: daily versus weekly administration.

Authors:  Y Ohbayashi; A Iwasaki; F Nakai; T Mashiba; M Miyake
Journal:  Osteoporos Int       Date:  2019-11-25       Impact factor: 4.507

2.  Bisphosphonate-associated osteonecrosis of the mandible: reliable soft tissue reconstruction using a local myofascial flap.

Authors:  Juliana Lemound; Andrè Eckardt; Horst Kokemüller; Constantin von See; Pit Jacob Voss; Frank Tavassol; Martin Rücker; Majeed Rana; Nils-Claudius Gellrich
Journal:  Clin Oral Investig       Date:  2011-08-05       Impact factor: 3.573

Review 3.  Macrophages and skeletal health.

Authors:  Megan N Michalski; Laurie K McCauley
Journal:  Pharmacol Ther       Date:  2017-02-07       Impact factor: 12.310

4.  Osteoconductive action of alendronate after implantation of beta tricalcium phosphate in rat adjuvant-induced arthritis.

Authors:  Takahiro Netsu; Naoki Kondo; Katsumitsu Arai; Akira Ogose; Naoto Endo
Journal:  J Bone Miner Metab       Date:  2012-07-18       Impact factor: 2.626

5.  Decrease in serum FGF23 levels after intravenous infusion of pamidronate in patients with osteogenesis imperfecta.

Authors:  Taichi Kitaoka; Noriyuki Namba; Kohji Miura; Takuo Kubota; Yasuhisa Ohata; Makoto Fujiwara; Haruhiko Hirai; Takehisa Yamamoto; Keiichi Ozono
Journal:  J Bone Miner Metab       Date:  2011-02-23       Impact factor: 2.626

Review 6.  Osteonecrosis of the Jaw-a Bone Site-Specific Effect of Bisphosphonates.

Authors:  Jenny A F Vermeer; Greetje A P Renders; Vincent Everts
Journal:  Curr Osteoporos Rep       Date:  2016-10       Impact factor: 5.096

7.  The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts.

Authors:  Angela C Hirbe; Anke J Roelofs; Desiree H Floyd; Hongju Deng; Stephanie N Becker; Lisa G Lanigan; Anthony J Apicelli; Zhiqiang Xu; Julie L Prior; Mark C Eagleton; David Piwnica-Worms; Michael J Rogers; Katherine Weilbaecher
Journal:  Bone       Date:  2009-01-23       Impact factor: 4.398

8.  Alterations in osteoclast function and phenotype induced by different inhibitors of bone resorption--implications for osteoclast quality.

Authors:  Anita V Neutzsky-Wulff; Mette G Sørensen; Dino Kocijancic; Diana J Leeming; Morten H Dziegiel; Morten A Karsdal; Kim Henriksen
Journal:  BMC Musculoskelet Disord       Date:  2010-06-01       Impact factor: 2.362

Review 9.  The chick chorioallantoic membrane: a model of molecular, structural, and functional adaptation to transepithelial ion transport and barrier function during embryonic development.

Authors:  Maria Gabriella Gabrielli; Daniela Accili
Journal:  J Biomed Biotechnol       Date:  2010-03-21

10.  Alendronate reduces osteoclast precursors in osteoporosis.

Authors:  P D'Amelio; A Grimaldi; M A Cristofaro; M Ravazzoli; P A Molinatti; G P Pescarmona; G C Isaia
Journal:  Osteoporos Int       Date:  2009-12-01       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.